APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)

Description

The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from kidney donors and recipients of kidney transplants for APOL1 to determine effects on kidney transplant-related outcomes.

Conditions

Kidney Diseases, Kidney Failure, Kidney Disease, Chronic

Study Overview

Study Details

Study overview

The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from kidney donors and recipients of kidney transplants for APOL1 to determine effects on kidney transplant-related outcomes.

APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)

APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)

Condition
Kidney Diseases
Intervention / Treatment

-

Contacts and Locations

Birmingham

University of Alabama at Birmingham, Birmingham, Alabama, United States, 35233

San Francisco

University of California San Francisco, San Francisco, California, United States, 94143

Miami

University of Miami / Miami Transplant Institute, Miami, Florida, United States, 33133

Atlanta

Emory University School of Medicine, Atlanta, Georgia, United States, 30322

Baltimore

University of Maryland School of Medicine, Baltimore, Maryland, United States, 21201

Baltimore

Johns Hopkins University, Baltimore, Maryland, United States, 21205

Boston

Joslin Diabetes Center / Harvard University, Boston, Massachusetts, United States, 02215

Ann Arbor

University of Michigan Medicine, Ann Arbor, Michigan, United States, 48109

Saint Louis

Saint Louis University Center for Transplantation, Saint Louis, Missouri, United States, 63104

New York

Ichan School of Medicine at Mount Sinai, New York, New York, United States, 10029

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    to

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    Wake Forest University Health Sciences,

    Barry I. Freedman, MD, PRINCIPAL_INVESTIGATOR, Wake Forest University Health Sciences

    David M. Reboussin, PhD, PRINCIPAL_INVESTIGATOR, Wake Forest University Health Sciences

    Paul L. Kimmel, MD, STUDY_DIRECTOR, Natl Institute of Diabetes, Digestive & Kidney Diseases

    Marva Moxey-Mims, MD, STUDY_CHAIR, Children's Natl Health System; George Washington Univ Sch of Med and Health Serv

    Study Record Dates

    2025-12-31